Depression - Pipeline Review, H1 2018

  • ID: 4479914
  • Report
  • 490 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4D Pharma PLC
  • BioCrea GmbH
  • DURECT Corp
  • Impel NeuroPharma Inc
  • Meta-IQ ApS
  • Pfizer Inc
  • MORE
Depression - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H1 2018, provides an overview of the Depression (Central Nervous System) pipeline landscape.

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. Treatment includes antidepressants, mood stabilizers or antipsychotics.

Report Highlights:

This Pharmaceutical and Healthcare latest pipeline guide Depression - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Depression (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Depression (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Depression and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 14, 30, 29, 1, 80, 14 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 13 and 7 molecules, respectively.

Depression (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Depression (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Depression (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Depression (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Depression (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Depression (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Depression (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Depression (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4D Pharma PLC
  • BioCrea GmbH
  • DURECT Corp
  • Impel NeuroPharma Inc
  • Meta-IQ ApS
  • Pfizer Inc
  • MORE
Introduction

Depression - Overview

Depression - Therapeutics Development

Depression - Therapeutics Assessment

Depression - Companies Involved in Therapeutics Development

Depression - Drug Profiles

Depression - Dormant Projects

Depression - Discontinued Products

Depression - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Depression, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Depression - Pipeline by 4D Pharma PLC, H1 2018

Depression - Pipeline by Acadia Pharmaceuticals Inc, H1 2018

Depression - Pipeline by Ache Laboratorios Farmaceuticos SA, H1 2018

Depression - Pipeline by Adamed Sp z oo, H1 2018

Depression - Pipeline by Addex Therapeutics Ltd, H1 2018

Depression - Pipeline by Aequus Pharmaceuticals Inc, H1 2018

Depression - Pipeline by Alkermes Plc, H1 2018

Depression - Pipeline by Allergan Plc, H1 2018

Depression - Pipeline by Amorsa Therapeutics Inc, H1 2018

Depression - Pipeline by Anavex Life Sciences Corp, H1 2018

Depression - Pipeline by Angelini Group, H1 2018

Depression - Pipeline by Avanir Pharmaceuticals Inc, H1 2018

Depression - Pipeline by Axsome Therapeutics Inc, H1 2018

Depression - Pipeline by Azevan Pharmaceuticals Inc, H1 2018

Depression - Pipeline by BioCrea GmbH, H1 2018

Depression - Pipeline by Blackthorn Therapeutics Inc, H1 2018

Depression - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Depression - Pipeline by Bristol-Myers Squibb Co, H1 2018

Depression - Pipeline by Calico LLC, H1 2018

Depression - Pipeline by Celgene Corp, H1 2018

Depression - Pipeline by Celon Pharma SA, H1 2018

Depression - Pipeline by Cerecor Inc, H1 2018

Depression - Pipeline by Clera Inc, H1 2018

Depression - Pipeline by ConSynance Therapeutics Inc, H1 2018

Depression - Pipeline by Delpor Inc, H1 2018

Depression - Pipeline by DURECT Corp, H1 2018

Depression - Pipeline by Eisai Co Ltd, H1 2018

Depression - Pipeline by Eli Lilly and Co, H1 2018

Depression - Pipeline by Evotec AG, H1 2018

Depression - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2018

Depression - Pipeline by FPRT Bio Inc, H1 2018

Depression - Pipeline by GlaxoSmithKline Plc, H1 2018

Depression - Pipeline by GliaCure Inc, H1 2018

Depression - Pipeline by H. Lundbeck AS, H1 2018

Depression - Pipeline by Heptares Therapeutics Ltd, H1 2018

Depression - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2018

Depression - Pipeline by Impel NeuroPharma Inc, H1 2018

Depression - Pipeline by Intas Pharmaceuticals Ltd, H1 2018

Depression - Pipeline by IntelGenx Corp, H1 2018

Depression - Pipeline by Intra-Cellular Therapies Inc, H1 2018

Depression - Pipeline by Johnson & Johnson, H1 2018

Depression - Pipeline by KemPharm Inc, H1 2018

Depression - Pipeline by Kissei Pharmaceutical Co Ltd, H1 2018

Depression - Pipeline by Lead Discovery Center GmbH, H1 2018

Depression - Pipeline by Les Laboratoires Servier SAS, H1 2018

Depression - Pipeline by Lixte Biotechnology Holdings Inc, H1 2018

Depression - Pipeline by Luye Pharma Group Ltd, H1 2018

Depression - Pipeline by Mapi Pharma Ltd, H1 2018

Depression - Pipeline by Mapreg SAS, H1 2018

Depression - Pipeline by Medlab Clinical Ltd, H1 2018

Depression - Pipeline by Meta-IQ ApS, H1 2018

Depression - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

Depression - Pipeline by Navitor Pharmaceuticals Inc, H1 2018

Depression - Pipeline by Navya Biologicals Pvt Ltd, H1 2018

Depression - Pipeline by Neuralstem Inc, H1 2018

Depression - Pipeline by Neurocrine Biosciences Inc, H1 2018

Depression - Pipeline by NeuroNascent Inc, H1 2018

Depression - Pipeline by Newron Pharmaceuticals SpA, H1 2018

Depression - Pipeline by Nippon Chemiphar Co Ltd, H1 2018

Depression - Pipeline by Novartis AG, H1 2018

Depression - Pipeline by Omeros Corp, H1 2018

Depression - Pipeline by Orexigen Therapeutics Inc, H1 2018

Depression - Pipeline by Otsuka Holdings Co Ltd, H1 2018

Depression - Pipeline by Pfizer Inc, H1 2018

Depression - Pipeline by Pherin Pharmaceuticals Inc, H1 2018

List of Figures

Number of Products under Development for Depression, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4D Pharma PLC
  • Acadia Pharmaceuticals Inc
  • Ache Laboratorios Farmaceuticos SA
  • Adamed Sp z oo
  • Addex Therapeutics Ltd
  • Aequus Pharmaceuticals Inc
  • Alkermes Plc
  • Allergan Plc
  • Amorsa Therapeutics Inc
  • Anavex Life Sciences Corp
  • Angelini Group
  • Avanir Pharmaceuticals Inc
  • Axsome Therapeutics Inc
  • Azevan Pharmaceuticals Inc
  • BioCrea GmbH
  • Blackthorn Therapeutics Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Calico LLC
  • Celgene Corp
  • Celon Pharma SA
  • Cerecor Inc
  • Clera Inc
  • ConSynance Therapeutics Inc
  • Delpor Inc
  • DURECT Corp
  • Eisai Co Ltd
  • Eli Lilly and Co
  • Evotec AG
  • Fabre-Kramer Pharmaceuticals Inc
  • FPRT Bio Inc
  • GlaxoSmithKline Plc
  • GliaCure Inc
  • H. Lundbeck AS
  • Heptares Therapeutics Ltd
  • Hyundai Pharmaceutical Co Ltd
  • Impel NeuroPharma Inc
  • Intas Pharmaceuticals Ltd
  • IntelGenx Corp
  • Intra-Cellular Therapies Inc
  • Johnson & Johnson
  • KemPharm Inc
  • Kissei Pharmaceutical Co Ltd
  • Lead Discovery Center GmbH
  • Les Laboratoires Servier SAS
  • Lixte Biotechnology Holdings Inc
  • Luye Pharma Group Ltd
  • Mapi Pharma Ltd
  • Mapreg SAS
  • Medlab Clinical Ltd
  • Meta-IQ ApS
  • Mitsubishi Tanabe Pharma Corp
  • Navitor Pharmaceuticals Inc
  • Navya Biologicals Pvt Ltd
  • Neuralstem Inc
  • Neurocrine Biosciences Inc
  • NeuroNascent Inc
  • Newron Pharmaceuticals SpA
  • Nippon Chemiphar Co Ltd
  • Novartis AG
  • Omeros Corp
  • Orexigen Therapeutics Inc
  • Otsuka Holdings Co Ltd
  • Pfizer Inc
  • Pherin Pharmaceuticals Inc
  • Protagenic Therapeutics Inc
  • Relmada Therapeutics Inc
  • Reviva Pharmaceuticals Inc
  • Richter Gedeon Nyrt
  • Sage Therapeutics Inc
  • Saniona AB
  • Shenox Pharmaceuticals LLC
  • SK Biopharmaceuticals Co Ltd
  • Sound Pharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Sunovion Pharmaceuticals Inc
  • Supernus Pharmaceuticals Inc
  • Syntropharma Ltd
  • Taisho Pharmaceutical Holdings Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Tetra Discovery Partners LLC
  • Trevena Inc
  • VistaGen Therapeutics Inc
  • Zysis Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll